BOSTON SCIENTIFIC CORP
BSXNYSEMedical Devices • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for BSX
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for BSX
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Exceed Consensus
Reported EPS of $0.86 per share exceeded the same-quarter consensus estimate of $0.83 per share for the period ended 2026-06-30.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $5.44bn, up 7.53% from $5.06bn for the quarter ended 2025-06-30.
Net Income Rises Year-Over-Year
Net income for the quarter ended 2026-06-30 was $905.0m, up 13.84% from $795.0m for the quarter ended 2025-06-30.
Gross Margin Expands
Gross margin for the quarter ended 2026-06-30 was 70.71%, wider than the 67.65% recorded for the quarter ended 2025-06-30.
Electrophysiology Segment Leads Growth
Electrophysiology EP revenue of $2.31bn was 11.5% of consolidated revenue for the period ended 2025-12-31, up 84.0% from $1.26bn in 2024-12-31.
Price Chart
NYSE:BSX via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
BSXBOSTON SCIENTIFIC CORP | $46.84 | $67.9B | 11.9x | 14.2x | +13.5% | 69.9% | 5.3% |
Company Profile
About the Company
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Next Earnings Date
Oct 28, 2026
Loading latest news...